Literature DB >> 30296409

PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome.

Antal Tapodi1, Zita Bognar1, Csaba Szabo2, Ferenc Gallyas3, Balázs Sumegi4, Enikő Hocsak1.   

Abstract

PURPOSE: The cytoprotective effect of poly(ADP-ribose) polymerase 1 (PARP1) inhibition is well documented in various cell types subjected to oxidative stress. Previously, we have demonstrated that PARP1 inhibition activates Akt, and showed that this response plays a critical role in the maintenance of mitochondrial integrity and in cell survival. However, it has not yet been defined how nuclear PARP1 signals to cytoplasmic Akt.
METHODS: WRL 68, HeLa and MCF7 cells were grown in culture. Oxidative stress was induced with hydrogen peroxide. PARP was inhibited with the PARP inhibitor PJ34. ATM, mTOR- and NEMO were silenced using specific siRNAs. Cell viability assays were based on the MTT assay. PARP-ATM pulldown experiments were conducted; each protein was visualized by Western blotting. Immunoprecipitation of ATM, phospho-ATM and NEMO was performed from cytoplasmic and mitochondrial cell fractions and proteins were detected by Western blotting. In some experiments, a continually active Akt construct was introduced. Nuclear to cytoplasmic and mitochondrial translocation of phospho-Akt was visualized by confocal microscopy.
RESULTS: Here we present evidence for a PARP1 mediated, PARylation-dependent interaction between ATM and NEMO, which is responsible for the cytoplasmic transport of phosphorylated (thus, activated) ATM kinase. In turn, the cytoplasmic p-ATM and NEMO forms complex with mTOR and Akt, yielding the phospho-ATM-NEMO-Akt-mTOR signalosome, which is responsible for the PARP-inhibition induced Akt activation. The phospho-ATM-NEMO-Akt-mTOR signalosome localizes to the mitochondria and is essential for the PARP-inhibition-mediated cytoprotective effects in oxidatively stressed cells. When the formation of the signalosome is prevented, the cytoprotective effects diminish, but cells can be rescued by constantly active Akt1, further confirming the critical role of Akt activation in cytoprotection.
CONCLUSIONS: Taken together, the data presented in the current paper are consistent with the hypothesis that PARP inhibition suppresses the PARylation of ATM, which, in turn, forms an ATM-NEMO complex, which exits the nucleus, and combines in the cytosol with mTOR and Act, resulting in Act phosphorylation (i.e. activation), which, in turn, produces the cytoprotective action via the induction of Akt-mediated survival pathways. This mechanism can be important in the protective effect of PARP inhibitor in various diseases associated with oxidative stress. Moreover, disruption of the formation or action of the phospho-ATM-NEMO-Akt-mTOR signalosome may offer potential future experimental therapeutic checkpoints.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; Cytotoxicity; Mitochondrion; Oxidative stress; Poly(ADP)ribose polymerase; Signaling

Year:  2018        PMID: 30296409     DOI: 10.1016/j.bcp.2018.10.005

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.

Authors:  Akbar Ahmad; Juliana de Camargo Vieira; Aline Haas de Mello; Thais Martins de Lima; Suely Kubo Ariga; Denise Frediani Barbeiro; Hermes Vieira Barbeiro; Bartosz Szczesny; Gábor Törö; Nadiya Druzhyna; Elisa B Randi; Michela Marcatti; Tracy Toliver-Kinsky; András Kiss; Lucas Liaudet; Reinaldo Salomao; Francisco Garcia Soriano; Csaba Szabo
Journal:  Pharmacol Res       Date:  2019-05-06       Impact factor: 7.658

Review 2.  Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.

Authors:  Palak Tiwari; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur Grewal
Journal:  Neurochem Res       Date:  2022-04-18       Impact factor: 3.996

3.  Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.

Authors:  Xi Zhang; Peng Huang; Liqiong Wang; Shu Chen; Basappa Basappa; Tao Zhu; Peter E Lobie; Vijay Pandey
Journal:  Cell Death Dis       Date:  2022-06-20       Impact factor: 9.685

4.  Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.

Authors:  Barbara A Frederick; Rohit Gupta; Amandla Atilano-Roque; Tin Tin Su; David Raben
Journal:  Radiat Res       Date:  2020-11-10       Impact factor: 2.841

Review 5.  Mitochondrial Protection by PARP Inhibition.

Authors:  Ferenc Gallyas; Balazs Sumegi
Journal:  Int J Mol Sci       Date:  2020-04-16       Impact factor: 5.923

Review 6.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

Review 7.  The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer.

Authors:  Daniel J Turnham; Nicholas Bullock; Manisha S Dass; John N Staffurth; Helen B Pearson
Journal:  Cells       Date:  2020-10-22       Impact factor: 6.600

Review 8.  Mammalian AKT, the Emerging Roles on Mitochondrial Function in Diseases.

Authors:  Xiaoxian Xie; Ruonan Shu; Chunan Yu; Zhengwei Fu; Zezhi Li
Journal:  Aging Dis       Date:  2022-02-01       Impact factor: 6.745

9.  Olaparib: A Clinically Applied PARP Inhibitor Protects from Experimental Crohn's Disease and Maintains Barrier Integrity by Improving Bioenergetics through Rescuing Glycolysis in Colonic Epithelial Cells.

Authors:  Dominika Kovács; Viola Bagóné Vántus; Eszter Vámos; Nikoletta Kálmán; Rudolf Schicho; Ferenc Gallyas; Balázs Radnai
Journal:  Oxid Med Cell Longev       Date:  2021-09-14       Impact factor: 6.543

10.  Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.

Authors:  Jesenia M Perez; Carly A I Twigg; Weihua Guan; Stefani N Thomas
Journal:  J Am Soc Mass Spectrom       Date:  2021-12-27       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.